Skip to main content
main-content

Keep up with the latest developments in rheumatology

News, expert interviews, & educational resources

FEATURED NEWS

14-04-2021 | Psoriatic arthritis | News

OPAL Balance supports long-term tofacitinib use for psoriatic arthritis

The final analysis of the OPAL Balance long-term extension study suggests that the JAK inhibitor tofacitinib has a consistent safety profile for up to 48 months in patients with psoriatic arthritis.

Podcasts

Interviews with experts rheumatologists on patient care

MOST READ | COVID-19 & rheumatic disease

09-04-2021 | COVID-19 | News

Researchers probe link between COVID-19 and autoimmunity

A large US study has evaluated the risk for developing incident rheumatic disease following a positive test for SARS-CoV-2.

COVID-19 vaccination in patients with rheumatic diseases

Get answers to key questions with recommendations from professional organizations.

MOST READ | JAK inhibitors

14-04-2021 | Psoriatic arthritis | News

OPAL Balance supports long-term tofacitinib use for psoriatic arthritis

The final analysis of the OPAL Balance long-term extension study suggests that the JAK inhibitor tofacitinib has a consistent safety profile for up to 48 months in patients with psoriatic arthritis.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

MOST READ | Inflammatory arthritis

12-04-2021 | Rheumatoid arthritis | News

Similar rheumatoid arthritis outcomes with oral vs subcutaneous methotrexate

Real-world study results suggest that patients with rheumatoid arthritis who initiate treatment with oral methotrexate achieve similar disease control to those taking the subcutaneous formulation.

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice.

Image Credits